AGMB (AgomAb Therapeutics NV) Common Stock: $261.21 Mil (As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Common Stock?

AgomAb Therapeutics NV AGMB +0.85% 14 Common Stock is $261.21 Mil as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

AgomAb Therapeutics NV's quarterly common stock increased from Dec. 2024 ($233.58 Mil) to Sep. 2025 ($261.82 Mil) but then declined from Sep. 2025 ($261.82 Mil) to Dec. 2025 ($261.21 Mil).

AgomAb Therapeutics NV's annual common stock increased from Dec. 2023 ($190.53 Mil) to Dec. 2024 ($233.58 Mil) and increased from Dec. 2024 ($233.58 Mil) to Dec. 2025 ($261.21 Mil).

AgomAb Therapeutics NV Common Stock Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Common Stock Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
95.37 116.96 190.53 233.58 261.21

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
Common Stock Get a 7-Day Free Trial 116.96 190.53 233.58 261.82 261.21
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $261.21 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Common Stock of $261.21 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Common Stock too high?
AgomAb Therapeutics NV's current Common Stock is $261.21 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Common Stock compare to DNA and ACRS?
AgomAb Therapeutics NV's Common Stock of $261.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Common Stock is $261.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Common Stock of $261.21 Mil. The current Common Stock is $261.21 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Common Stock is $261.21 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price